PHARMEP
PHARMEP has been active since 2010 and the Belgian State Gazette contains no insolvency or warning signals. The 2024 annual accounts show equity of €643k and a net result of €42k. Equity is growing by ~10.9% per year across the filed fiscal years. Its solvency ranks better than 47% of 4626 sector peers (fiscal year 2024). The computed 12-month bankruptcy probability is 0.2% (very low).
| Equity | €643k |
| Net result | €42k |
| Better than sector | 47% |
| Active | 15 yrs |
Mixed profile: strong on stability, weaker on profitability.
All 5 axes are computed from data Checked has read.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 45.3% | 48.8% | |
| Net result | €42k | €45k | |
| Equity | €643k | €529k | |
| Gross operating margin | €79k | €82k | |
| Total assets | €1.42M | €1.52M |
Figures by fiscal year and ratios
| Fiscal year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Deposit | full schema | full schema | full schema | full schema |
| Revenue | - | - | - | - |
| EBITDA | €77k | €79k | €69k | €77k |
| Net profit | €42k | €69k | €65k | €73k |
| Cash flow | €45k | €73k | €69k | €77k |
| Staff costs | - | - | - | - |
| Income taxes | €16k | €20k | €18k | €22k |
| Dividends | - | - | - | - |
| Total assets | €1.42M | €1.42M | €1.43M | €1.43M |
| Equity | €643k | €601k | €531k | €466k |
| Debt | €775k | €819k | €903k | €961k |
| of which ≤ 1y | €383k | €350k | €443k | €462k |
| of which > 1y | €392k | €469k | €459k | €499k |
| Working capital | €-374k | €-343k | €-424k | €-437k |
| Employees (FTE) | - | - | - | - |
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Current ratio | 0.02 | 0.02 | 0.04 | 0.05 |
| Quick ratio | 0.02 | 0.02 | 0.04 | 0.05 |
| Working capital ratio | -26.4% | -24.1% | -29.6% | -30.6% |
| Solvency | 45.3% | 42.3% | 37.0% | 32.7% |
| Debt / equity | 1.21 | 1.36 | 1.70 | 2.06 |
| Long-term debt ratio | 0.61 | 0.78 | 0.86 | 1.07 |
| Interest coverage | 5.03 | 5.58 | 5.83 | 25.08 |
| Gross margin | - | - | - | - |
| Net margin | - | - | - | - |
| ROA | 2.9% | 4.9% | 4.5% | 5.1% |
| ROE | 6.5% | 11.6% | 12.2% | 15.7% |
| EBITDA margin | - | - | - | - |
| Days sales outstanding | - | - | - | - |
| Days payable outstanding | - | - | - | - |
| Inventory turnover | - | - | - | - |
| Days inventory (DSI) | - | - | - | - |
Full annual accounts (24 line items)
| Line item | Code | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Balance sheet, Assets | |||||
| TOTAL ASSETS | 20/58 | €1.42M | €1.42M | €1.43M | €1.43M |
| Fixed assets | 21/28 | €1.41M | €1.41M | €1.42M | €1.40M |
| Tangible fixed assets | 22/27 | €9k | €12k | €16k | €3k |
| Financial fixed assets | 28 | €1.40M | €1.40M | €1.40M | €1.40M |
| Current assets | 29/58 | €9k | €8k | €19k | €25k |
| Amounts receivable within one year | 40/41 | €8 | - | €402 | - |
| Cash & bank | 54/58 | €9k | €8k | €18k | €25k |
| Balance sheet, Equity & liabilities | |||||
| TOTAL EQUITY & LIABILITIES | 10/49 | €1.42M | €1.42M | €1.43M | €1.43M |
| Equity | 10/15 | €643k | €601k | €531k | €466k |
| Contributions / capital | 10/11 | €20k | €20k | €20k | €20k |
| Reserves | 13 | €299k | €257k | €187k | €122k |
| Accumulated profits (losses) | 14 | €324k | €324k | €324k | €324k |
| Amounts payable | 17/49 | €775k | €819k | €903k | €961k |
| Amounts payable after one year | 17 | €392k | €469k | €459k | €499k |
| Amounts payable within one year | 42/48 | €383k | €350k | €443k | €462k |
| Trade debts payable within one year | 44 | €1k | €361 | €631 | €436 |
| Income statement | |||||
| Gross operating margin | 9900 | €79k | €81k | €71k | €78k |
| Operating result | 9901 | €73k | €75k | €65k | €73k |
| Financial income | 75 | - | €28k | €30k | €25k |
| Financial charges | 65 | €15k | €14k | €12k | €3k |
| Result before taxes | 9903 | €58k | €89k | €83k | €95k |
| Income taxes | 67/77 | €16k | €20k | €18k | €22k |
| Net result for the period | 9904 | €42k | €69k | €65k | €73k |
| Result to be appropriated | 9905 | €42k | €69k | €65k | €73k |
-
Paul MEURANTDirectorState Gazette act 23471549 (21-12-2023)Current21-12-2023 → present
| NACE primary | Business and other management consultancy(70200) |
| Legal form | Private limited company(610) |
| Incorporation | 20-10-2010 |
| Status | Active |
| Postal code | 7021 |
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 53038B0414/00P000 | Wallonia | 221 m² | 1 · 134 m² | 13.4 m · 4 fl. |
We know of 2 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
21-12-2023 Paul MEURANT appointed as director
- Paul MEURANT, Bestuurder
Technical details
{
"events": [
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Paul MEURANT",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "renewal",
"via_org": null,
"statutory": "niet_statutair",
"compensated": true,
"effective_date": null,
"evidence_quote": "L\u2019assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide de mettre fin \u00E0 la fonction du g\u00E9rant actuel, mentionn\u00E9 ci-apr\u00E8s, et proc\u00E8de imm\u00E9diatement au renouvellement de sa nomination comme administrateur non statutaire pour une dur\u00E9e illimit\u00E9e : Monsieur Paul MEURANT, ci \u2013 avant qualifi\u00E9, ici pr\u00E9sent et qui accepte.",
"decharge_status": null,
"mandate_duration": {
"kind": "indefinite",
"value": null
},
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": "immediate"
},
{
"kind": "decharge_pending",
"role": "g\u00E9rant",
"person": {
"rrn": null,
"name": "Paul MEURANT",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": null,
"via_org": null,
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "L\u2019assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cidera \u00E0 la prochaine assembl\u00E9e g\u00E9n\u00E9rale annuelle sur la d\u00E9charge au g\u00E9rant d\u00E9missionnaire pour l\u2019ex\u00E9cution de son mandat.",
"decharge_status": "pending_next_agm",
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
}
],
"notary": {
"name": "Edmond-Charles BOUTTIAU",
"firm_city": null,
"firm_name": null,
"office_city": "Qu\u00E9vy",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2023-12-21",
"filing_date": "2023-12-19",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decisions": [
{
"body": "algemene_vergadering",
"date": "2023-12-11",
"unanimous": true
},
{
"body": "algemene_vergadering",
"date": "2023-12-11",
"unanimous": true
},
{
"body": "algemene_vergadering",
"date": "2023-12-11",
"unanimous": true
},
{
"body": "algemene_vergadering",
"date": "2023-12-11",
"unanimous": true
},
{
"body": "algemene_vergadering",
"date": "2023-12-11",
"unanimous": true
},
{
"body": "algemene_vergadering",
"date": "2023-12-11",
"unanimous": true
},
{
"body": "algemene_vergadering",
"date": "2023-12-11",
"unanimous": true
},
{
"body": "algemene_vergadering",
"date": "2023-12-11",
"unanimous": true
}
],
"is_correction": false,
"subject_company": {
"kbo": "0830.777.581",
"name_full": "PHARMEP",
"legal_form": "SRL"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Edmond-Charles BOUTTIAU",
"org_rep_person_name": null,
"person_role_at_subject": "Notaire"
},
"co_filed_documents": [
"Une exp\u00E9dition de l\u0027AGE du 11 d\u00E9cembre 2023",
"les statuts coordonn\u00E9s"
],
"corrected_publication_numac": null
}| Legal nameFR | PHARMEP |